Additionally, we have proposed a hypothesis suggesting that MPO and TRH expression levels within LSCs could serve as robust biomarkers for predicting therapeutic responses in AML patients undergoing ‘7 + 3’ induction therapy. Here, TRH is linked to acute myeloid leukemia.